Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl M Gay

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Clinical Lung Cancer|July 13, 2024
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLCMartin Reck, Ernest Nadal, Nicolas Girard, et al.
Frontiers in Oncology|May 12, 2020
Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER DatabaseYuyan Wang, Qiwen Zheng, Bo Jia, et al.
The Oncologist|July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCarl M Gay, Yanhong Zhou, J Jack Lee, et al.
Cell Discovery|September 4, 2024
Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancerYing Jin, Yuefeng Wu, Alexandre Reuben, et al.
Cell Discovery|December 20, 2024
Author Correction: Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancerYing Jin, Yuefeng Wu, Alexandre Reuben, et al.
JTO Clinical and Research Reports|January 26, 2026
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From <i>ALK</i>-Rearranged NSCLC: Case ReportKaiwen Wang, Ceylan Altintas Taslic, Patricia de Groot, et al.
CA: a Cancer Journal for Clinicians|June 17, 2023
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directionsZsolt Megyesfalvi, Carl M Gay, Helmut Popper, et al.
Cancer & Metabolism|September 24, 2021
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancerKasey R Cargill, C Allison Stewart, Elizabeth M Park, et al.
Signal Transduction and Targeted Therapy|October 4, 2022
Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancerYanhua Tian, Qingqing Li, Zhenlin Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung CancerKavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Clinical Lung Cancer|July 13, 2024
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLCMartin Reck, Ernest Nadal, Nicolas Girard, et al.
Frontiers in Oncology|May 12, 2020
Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER DatabaseYuyan Wang, Qiwen Zheng, Bo Jia, et al.
The Oncologist|July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCarl M Gay, Yanhong Zhou, J Jack Lee, et al.
Cell Discovery|September 4, 2024
Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancerYing Jin, Yuefeng Wu, Alexandre Reuben, et al.
Cell Discovery|December 20, 2024
Author Correction: Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancerYing Jin, Yuefeng Wu, Alexandre Reuben, et al.
JTO Clinical and Research Reports|January 26, 2026
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From <i>ALK</i>-Rearranged NSCLC: Case ReportKaiwen Wang, Ceylan Altintas Taslic, Patricia de Groot, et al.
CA: a Cancer Journal for Clinicians|June 17, 2023
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directionsZsolt Megyesfalvi, Carl M Gay, Helmut Popper, et al.
Cancer & Metabolism|September 24, 2021
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancerKasey R Cargill, C Allison Stewart, Elizabeth M Park, et al.
Signal Transduction and Targeted Therapy|October 4, 2022
Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancerYanhua Tian, Qingqing Li, Zhenlin Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung CancerKavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, et al.
Pageof 8